IL2 and hematopoietic and lymphoid cell neoplasm: Following the initial reports of solid tumor regression following high-dose systemic IL-2 as early as 1985 (45), subsequent efforts demonstrated NK cell efficacy in eliminating both solid and hematologic cancers in animal models and clinical trials (31, 32, 46–48).